Second Sight Medical Products is a medical devices business based in the US. Second Sight Medical Products shares (EYES) are listed on the NASDAQ and all prices are listed in US Dollars. Second Sight Medical Products employs 15 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $2.22 |
|---|---|
| 52-week range | $1.14 - $5.28 |
| 50-day moving average | $1.90 |
| 200-day moving average | $1.97 |
| Wall St. target price | $2.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.23 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.22 from 2022-07-05
| 1 week (2022-06-30) | 9.36% |
|---|---|
| 1 month (2022-06-06) | -10.48% |
| 3 months (2022-04-07) | 58.57% |
| 6 months (2022-01-03) | N/A |
| 1 year (2021-07-07) | -46.63% |
|---|---|
| 2 years (2020-07-07) | 145.30% |
| 3 years (2019-07-05) | 182.16% |
| 5 years (2017-07-07) | 83.47% |
| Revenue TTM | $497,000 |
|---|---|
| Gross profit TTM | $130,000 |
| Return on assets TTM | -10.74% |
| Return on equity TTM | -19.02% |
| Profit margin | 0% |
| Book value | $1.68 |
| Market capitalisation | $80 million |
TTM: trailing 12 months
We're not expecting Second Sight Medical Products to pay a dividend over the next 12 months.
Second Sight Medical Products's shares were split on a 1:8 basis on 5 January 2020. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Second Sight Medical Products shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Second Sight Medical Products shares which in turn could have impacted Second Sight Medical Products's share price.
Over the last 12 months, Second Sight Medical Products's shares have ranged in value from as little as $1.14 up to $5.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Second Sight Medical Products's is 2.8153. This would suggest that Second Sight Medical Products's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.